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Abstract
Human cancers are driven by the acquisition of somatic mutations. Separating the driving mutations from those that are
random consequences of general genomic instability remains a challenge. New sequencing technology makes it possible to
detect mutations that are present in only a minority of cells in a heterogeneous tumor population. We sought to leverage
the power of ultra-deep sequencing to study various levels of tumor heterogeneity in the serial recurrences of a single
glioblastoma multiforme patient. Our goal was to gain insight into the temporal succession of DNA base-level lesions by
querying intra- and inter-tumoral cell populations in the same patient over time. We performed targeted ‘‘next-generation’’
sequencing on seven samples from the same patient: two foci within the primary tumor, two foci within an initial
recurrence, two foci within a second recurrence, and normal blood. Our study reveals multiple levels of mutational
heterogeneity. We found variable frequencies of specific EGFR, PIK3CA, PTEN, and TP53 base substitutions within individual
tumor regions and across distinct regions within the same tumor. In addition, specific mutations emerge and disappear
along the temporal spectrum from tumor at the time of diagnosis to second recurrence, demonstrating evolution during
tumor progression. Our results shed light on the spatial and temporal complexity of brain tumors. As sequencing costs
continue to decline and deep sequencing technology eventually moves into the clinic, this approach may provide guidance
for treatment choices as we embark on the path to personalized cancer medicine.
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Introduction
Human cancers are typically categorized into subtypes based on
tissue of origin and/or histopathology. As larger numbers of
individual tumors are characterized at ever-higher molecular
resolution it is clear that there is substantial mutational
heterogeneity across patients, even within the same histopatho-
logical subtype. There are two additional levels of heterogeneity
that are seldom studied: intra-tumor heterogeneity and heteroge-
neity of the subpopulations evolving over time. A consequence of
intra-tumor heterogeneity is that crucial mutations may be present
in only a subset of cells. Moreover, treatments may lead to selective
expansion or regression of particular subpopulations within the
original tumor, particular when it evolves to a recurrence or
metastasis. Researchers have begun to take advantage of such
intra-patient heterogeneity, inferring the mechanisms and tempo-
ral sequence of events in metastasis in pancreatic carcinoma [1,2]
and breast cancer [3,4].
Gliomas are known for their inter- and intra-patient heteroge-
neity, and represent a substantial challenge for the surgeon. A
persistent problem during surgery is precise resection of a
maximum amount of malignant cells while preserving healthy
brain tissue. Glioblastoma multiforme (GBM) is the most common
primary brain malignancy in adults, accounting for some 13,000
deaths per year in the United States [5]. In addition to surgery,
treatment for GBM patients generally consists of radiotherapy and
chemotherapy. Unfortunately, these treatments are rarely curative
and the vast majority of tumors recur locally within the brain. At
present, it is unknown whether the primary reason for this is
lingering malignant cells, de novo clonal expansions, selective
pressures from adjuvant radiation/chemotherapeutic treatment,
or some other mechanism [6–8]. Although a subset of patients
show increased survival with concurrent radiation and chemo-
therapy, there is an urgent need for better treatments [9].
To help gain understanding that may lead to new therapeutic
options, some recent studies have aimed to identify specific
mutations, genes, and molecular pathways driving gliomagenesis.
Two such large-scale efforts [10,11] included in their strategies
targeted capillary-based sequencing of genes across large numbers
of tumor samples. Performing Sanger sequencing at one tumor
region per patient can be problematic, however, because of cell-to-
cell molecular heterogeneity within each region, as well as region-
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samples are frequently extremely admixed, making accurate
detection of the tumor-specific mutational signature non-trivial.
Expanding the knowledge of the mutational spectrum of matched
sets of primaries and recurrences for patients with GBM may shed
light on this molecular heterogeneity and the temporal sequence of
mutations that arise in response to the selective pressures of
radiation and/or chemotherapy.
Technologies for interrogation of the cancer genome have
decreased in cost and exploded in throughput over the last decade.
Most recently, ‘‘next-generation’’ sequencing has emerged as a
crucial tool in this effort [12]. The new sequencing technologies
are capable of producing tens of millions of short (75–100 bp)
reads in a single experiment with cost currently around $1,000 and
decreasing. Critically, each read represents the sequence of single
DNA molecule, rather than the combined signal from all cells in
the sample, as is the case in Sanger sequencing. As a result, the
new technology is able to detect mutations that are present in a
small minority of cells [13]. Here we sought to characterize tumor
heterogeneity across various tumor regions as well as over time
using a single lane of sequence from a widely-used next-generation
sequencing platform. We interrogate seven distinct samples from a
single GBM patient, targeting genes known to have important
roles in glioblastoma [10,11,14–16]. Leveraging the platform’s
power to detect low-frequency mutations, our goal was to
characterize heterogeneity with regard to both presence and
cellular frequency within each tumor region. This approach may
serve as a paradigm for the pursuit of personalized medicine in the
setting of brain cancer.
Materials and Methods
Ethics Statement
The Case Cancer Institutional Review Board approved all
activities pertaining to the study. Written informed consent was
obtained from the participant.
Patient samples and DNA extraction
The patient was a male of European ancestry, diagnosed at age
69 with primary GBM and subsequent double GBM recurrence.
Treatment for the primary tumor involved surgical resection
followed by concurrent radiotherapy and temozolomide chemo-
therapy, and then adjuvant temozolomide chemotherapy [9].
Treatment for the first recurrence involved surgical resection
followed by chemotherapy with thalidomide and bevicizumab.
Treatment for the second recurrence involved surgical resection
only. Time between primary diagnosis and first recurrence was 6
months. Time between first and second recurrences was 3
months, and overall survival time from primary diagnosis was 11
months. After en block resection, pieces of the most representative
portion of each tumor were dissected into 0.1–0.2 g aliquots and
snap-frozen in liquid nitrogen within five minutes of resection
using an IRB-approved protocol. H&E staining was performed
by a trained neuro-pathologist using a six-micron re-cut of tumor
tissue. Proportion tumor nuclei ranged from 10–60% and
proportion necrosis ranged from 10–90%, which is typical in
resected brain tumors. This study examined normal blood
obtained at the time of diagnosis, and two randomly selected
specimens from each of the three resected tumors (Figure 1).
DNA was extracted from whole blood and from 25 mg of each
snap frozen tumor sample using the QIAamp DNA Mini Kit
(Qiagen Ltd) as per manufacturer’s instructions for each
biospecimen type.
Gene selection
Since the aim of this study was to characterize mutational
heterogeneity, we selected genes that have been reported as being
frequently altered in GBM in previous studies. Using published
lists of frequently altered genes [10,11,14–16], we selected ten –
CDKN2A, CDKN2B, EGFR, IDH1, IDH2, NF1, PIK3CA, PIK3R1,
PTEN, and TP53 – for exon sequencing.
Exon amplification and barcoding
Primers were designed using ExonPrimer (http://ihg2.
helmholtz-muenchen.de/ihg/ExonPrimer.html) for PCR amplifi-
cation of exons. Target specificity was assessed using electronic
PCR [17]. A total of 107 primer pairs covering 168 exons of 10 the
target genes were designed in total (Table S1). Following
purification using the QIAquick PCR Purification Kit (Qiagen
Ltd; Valencia, CA), PCR products from a single sample were
pooled together and sonically fragmented to sizes of 100–200 bp
using adaptive focused acoustic technology (Covaris; Woburn,
MA). After shearing, adapters including a unique sample-specific
barcode 7 bp in length and universal sequencing primers were
ligated to either end of the DNA fragment. The resulting ligation
products were run on an agarose gel, fragments 150–200 bp were
gel-excised and extracted from the agarose, and a second PCR was
performed using the universal sequencing primers. Following an
additional purifications step, all the bar-coded samples were
pooled together and delivered to the High-Throughput Sequenc-
ing Core Facility at the Case Western Reserve University
Comprehensive Cancer Center.
Ultra-deep sequencing
Reads of 75 bases were generated using the single-end protocol
of the Illumina Genome Analyzer II. Exact duplicates were
discarded as potential PCR artifact. The 7-base barcode
subsequences were used to uniquely assign each read to its parent
sample, then removed in silico. The resulting 68-base reads were
next base-quality filtered as follows. If all bases had quality scores
above 22, the read was left intact. Otherwise, the read was split
into 34-base halves. Halves with any base quality score below 23
were discarded. The combined set of 34- and 68-base reads was
then aligned to the reference human genome sequence (hg18)
using the MAQ software [18], and poor read alignments were
removed according to the software defaults.
Allele frequency and mutation calling
A single-base deviation from the human reference genome
sequence within a target exon was flagged as a possible single
Figure 1. Sample set schematic. This schematic gives a conceptual
view of the seven GBM patient samples interrogated in this study. From
left to right, we will refer to them in this manuscript as: primary tumor
A, primary tumor B, first recurrence A, first recurrence B, second
recurrence A, second recurrence B, and blood.
doi:10.1371/journal.pone.0035262.g001
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least seven independent reads, at least one of which came from
each of the positive and negative strands; (ii) at least 10% of the
reads carried the same non-reference allele; (iii) the base did not
lie within a homopolymer repeat; and (iv) the base did not
correspond to an alternate allele in a pseudogene region. The
SNV sites were then queried in all other samples. Mutations with
allele frequencies below 5% were disregarded as potential
sequencing errors.
Pyrosequencing and TA cloning validation
Pyrosequencing was performed as previously described [19,20].
Briefly, PCR amplification products from all seven samples were
delivered to the pyrosequencing facility in a blinded manner and
sequenced using the sequencing primers designed specifically for
the PyroMark MD pyrosequencing instrument (Biotage) as per the
manufacturer’s instructions. Each experiment was performed in
triplicate, and the mean of the estimates is reported. For TA
cloning, the region harboring the putative mutation was PCR-
amplified, and the amplicon was inserted into the pGEM vector
Figure 2. Distinguishing germline variants from somatic variants. (A) For each SNP, the non-reference allele frequencies for samples (out of
seven) with smallest (black) and largest (gray) such frequencies are shown. In all samples, these frequencies do not deviate substantially from the
germline frequencies. All SNPs in all samples have minor allele frequencies near the expected 50% or 100% and are therefore clearly and consistently
distinguishable as either homozygotes (leftmost three) or heterozygotes (the remainder). (B) In contrast, the somatic variants display much wider
ranges in allele frequencies across samples. Note that the absence of black bars is indicative complete absence of the mutation in some samples.
doi:10.1371/journal.pone.0035262.g002
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products were then transformed into DHa5 (Invitrogen) compe-
tent bacterial cells. The reaction includes a heat shock step
followed by plating onto LB plates with ampicillin, X-gal and
IPTG for selection of the transformed product. Positive colonies
were used as an innoculum for growing up the clones in 200 mlL B
Table 1. Somatic mutations.
Sample Gene Chromosome Position Ref Alt No. Read No. Ref No. Alt % Alt
Amino Acid
Change
Blood PTEN 10 89643788 G 78 77 0 0
primary tumor A PTEN 10 89643788 G A 122 93 29 23.8 G36R
primary tumor B PTEN 10 89643788 G A 52 39 13 25 G36R
first recurrence B PTEN 10 89643788 G A 100 71 29 29 G36R
Blood TP53 17 7517819 G A 388 383 4 1.0
second recurrence B TP53 17 7517819 G A 405 355 50 12.4 R282W
Blood TP53 17 7520197 G 163 160 0 0
second recurrence B TP53 17 7520197 G C 215 188 27 12.6 P72R
Blood PIK3CA 3 180420432 T 25 25 0 0
primary tumor A PIK3CA 3 180420432 T C 23 21 2 8.7 V638A
primary tumor B PIK3CA 3 180420432 T C 13 12 1 7.7 V638A
first recurrence A PIK3CA 3 180420432 T C 14 13 1 7.1 V638A
second recurrence B PIK3CA 3 180420432 T C 53 46 7 13.2 V638A
Blood EGFR 7 55233911 T C 669 6 663 99.1 T903T
second recurrence B EGFR 7 55233911 T C 603 146 457 75.8 T903T
Read counts in the blood sample are shown as a reference control.
doi:10.1371/journal.pone.0035262.t001
Figure 3. Validation of PTEN mutation. For the sequencing data, the percentage of reads harboring the mutation (horizontal axis) is used as an
estimate of the mutation frequency in each sample, plotted against the pyrosequencing frequency estimates (vertical axis; see Materials and
Methods).
doi:10.1371/journal.pone.0035262.g003
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clone, sequencing was performed directly from the bacterial
cultures on an ABI 3730 DNA Sequencer.
Results
Coverage Metrics
After the filtering steps described in the Materials and Methods
section, the mean sequence coverage across all samples for the
bases in the interrogated exons was 124 reads per base (sample
mean range 81–145). Although the sequence coverage varied
substantially among genes, coverage within each gene was quite
consistent across samples (Figure S1). Differences in gene coverage
were therefore most likely either the result of differential PCR
efficiency that was consistent across samples, or of varying degrees
of non-unique reference sequence within codons.
Candidate mutations
Using the criterion described in Materials and Methods, we
flagged 22 nucleotide positions as candidate SNVs (Table S2). Of
these, 18 were identified in the normal blood (and in the tumor
samples) and are all annotated as single nucleotide polymorphisms
(SNPs) in the dbSNP database (http://www.ncbi.nlm.nih.gov/
projects/SNP/). Such known SNPs provide convenient control
sites with which to assess the accuracy of the read allele frequency
as a measure of actual sample allelic content. Specifically, in the
germline and tumor samples unaffected by copy number
aberrations, we would expect non-reference allele read counts
near either 50% (for heterozygotes) or 100% (for non-reference
allele homozygotes) at these SNPs. This signature is clear
throughout all samples in 17 of the 18 SNPs (Figure 2A) which
attests to the precision of read count proportion as a measure of
true frequency. This left five sites as candidate somatic mutations
(Figure 2B and Table 1). These include the remaining SNP, a
silent variant in EGFR that is clearly a minor allele homozygote in
all samples except the second recurrence B, where it reverts to a
heterozygote in approximately half of the cells.
Independent validation
To guard against false-positive mutation calls that can arise
from technological artifacts – particularly in emerging technologies
such as next-generation sequencers – we validated somatic
alterations using two independent methods. The relatively low
mutational frequencies (Table 1) make reliable detection chal-
Figure 4. Spatial and temporal mutational heterogeneity. For each sample, the percentage of reads harboring each mutation is plotted. If a
mutation is present in a heterozygous constellation, the percentage of cells carrying it will be approximately twice the read percentage displayed
here.
doi:10.1371/journal.pone.0035262.g004
Table 2. Computational classifications of mutations.
Gene Chromosome Position Amino Acid Change SIFT Prediction PolyPhen Prediction
CanPredict
Prediction
PTEN 10 89643788 G36R DAMAGING Probably Damaging Likely Cancer
TP53 17 7517819 R282W DAMAGING Probably Damaging Likely Cancer
TP53 17 7520197 P72R TOLERATED Benign Likely Not Cancer
PIK3CA 3 180420432 V638A TOLERATED Benign Likely Not Cancer
EGFR 7 55233911 synonymous N/A N/A N/A
doi:10.1371/journal.pone.0035262.t002
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presence and frequencies of the mutations across all samples, we
performed pyrosequencing (see Materials and Methods) of the
PTEN mutation site in all seven samples. Pyrosequencing allows
simultaneous detection and quantification of specific nucleotide
residues. For each sample, the resulting mutational frequency
estimates were remarkably consistent between the Illumina
sequence output and pyrosequencing (Figure 3). We also validated
the PTEN and TP53 R282W mutations by sequencing multiple
TA clones generated from samples harboring the mutations
(Figure S2).
Prior reports and functional impact of detected
mutations
One of the goals in this study was to distinguish between the
mutations driving tumor initiation and recurrence from those that
are passenger consequences of treatment and/or general genomic
instability, or whose presence does not confer resistance to
standard therapies. The PTEN codon 36 that is altered in three
of the samples has been reported by other groups to be quite
frequently mutated somatically, particularly in GBM. The
COSMIC database [22] cites six cases of GBM with alterations
in PTEN codon 36, one of which has the same G36R mutation as
our study’s patient. The Cancer Genome Atlas GBM study [10]
reports one sample with a G36E mutation. Regarding TP53, the
R282W substitution is one of the most common across many
tumor types, and is reported in 20 brain tumors in the COSMIC
database, as well as in two of the 206 TCGA GBM samples. On
the other hand, the P72R mutation is actually at the site of a
common SNP, rs1042522 (minor allele frequency 23.3% in
HapMap [23] European ancestral samples (CEU)) and has not
been previously reported as a somatic mutation. Similarly, the
mutated EGFR site is a SNP (rs1140475) that has not been
previously reported as a somatic mutation, nor has any site in the
PIK3CA codon 638.
To determine whether the somatic substitutions are potentially
deleterious, we queried them using three widely-used computa-
tional tools: SIFT [24], CanPredict [25], and PolyPhen-2 [26]
(Table 2). All of these aim to classify the impact of amino acid
changes on protein function by analyzing cross-species conserva-
tion of the residue, biochemical properties of the amino acid
sequence, curated literature, and other sources. The PTEN G36R
substitution that dominates the mutational landscape (Figure 4) of
the primary and first recurrence samples is classified as deleterious
by all four tools. However, as the patient progresses to the second
recurrence, three of the four other mutations were either silent or
classified as benign, with only the TP53 R282W substitution
deemed deleterious.
Contrasting mutational and histopathological landscapes
Having established mutational heterogeneity among our set of
patient samples, we sought to determine the degree to which the
heterogeneity was reflected in the histopathology. Figure 5 shows
the H&E-stained re-cuts of the three tumor samples – primary,
first recurrence, and second recurrence. Though morphologies
differ considerably from primary to first recurrence to second
recurrence, each individual image shows a fairly uniform
pathology. Thus, the histopathology is somewhat indicative of
the underlying molecular landscape, but is not sufficiently sensitive
to recapitulate all of the mutational heterogeneity.
A model for gliomagenesis and recurrence in this patient
The spatial and temporal heterogeneity characterized in our
study (Figure 4) facilitates the construction of a putative model
specific to this patient’s individual disease. Prior to treatment, a
subclonal population arose with a PTEN mutation, present in
Figure 5. Histopathology of the primary tumor and recurrenc-
es. The primary tumor (top) shows uniform cellularity with moderate
pleomorphism. The first recurrence (middle) demonstrates marked
nuclear pleomorphism and regions of necrosis, while the second
recurrence (bottom) shows enlarged, moderately pleomorphic nuclei.
doi:10.1371/journal.pone.0035262.g005
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at least partially driving the primary tumor, given the multiple
previous reports of the same codon being mutated in GBM as well
as the substitution’s deleterious classification (see above). The
primary tumor also harbored a PIK3CA mutation in a small subset
of cells. No published studies report this codon as being mutated,
however, and the classification algorithms suggest that it is likely a
passenger mutation. In any case, the PTEN and PIK3CA mutations
appear in separate subclonal populations, as evidenced by their
mutual exclusivity in the first recurrence (with focus A harboring
the PIK3CA lesion and focus B the PTEN lesion). Although the
initial round of surgery, chemotherapy, and radiation did not
eradicate the cells with the driver mutation, the second round
appears to have done so. Indeed, the second recurrence has no
evidence of PTEN mutation, but the subclonal population
harboring the PIK3CA mutation seems to have acquired a
‘‘hypermutator’’ phenotype, acquiring three new observed (and
certainly many more unobserved) mutations. It should be noted
that we observed no mutations in recurrence A among the
interrogated genes, underscoring the potential pitfall of drawing
broad conclusions from only a specific region of a heterogeneous
tumor.
Discussion
Our work here highlights heterogeneity within tumors and their
cellular subpopulations, and also describes mutational differences
between primary tumors and recurrences. Although sets of
primary tumors and metastases have been previously studied by
some groups for genomic heterogeneity [1,2,27], analogous studies
of sequential recurrences as presented here are uncommon. This is
due to the difficulty of finding matched sets of properly preserved
samples and the necessity of very high depth sequencing coverage
across all samples in order to detect mutations that appear only in
a minority of cells in a sample. The signals from such mutations
are often below the noise threshold in Sanger sequence reads [21],
and therefore likely remain underreported in the literature. We
were able to accurately call mutations that were present in
frequencies as low as 10%. Interestingly, the 10% threshold of
detection was also cited in a recent study [28] of heteroplasmy in
mitochondrial genomes using next-generation sequencing.
The results presented here establish several important princi-
ples. First, it is crucial that researchers do not rely solely on
capillary-based sequencing for mutation detection and validation,
since molecular heterogeneity may obscure important lesions.
Second, filtering out annotated SNPs from lists of putative somatic
substitutions can lead to false negatives because the mutation may
occur at a known SNP. Some sites are assigned SNP IDs (i.e. rs
numbers) based on scant validation, as is the case with the R282W
substitutions reported here in TP53. The SNP (rs28934574) was
reported only by one group in a single sample in dbSNP (www.
ncbi.nlm.nih.gov/projects/SNP/). Even well-validated SNPs may
be the site of somatic mutation simply by chance. Third, a single
sample of tumor tissue might not be representative of other regions
within the tumor (and may itself be an amalgamation of subclonal
populations), and primary tumor samples do not necessarily
represent the clonal origin of future recurrences.
Our proof-of-principle study required only one lane of
sequencing on the Illumina Genome Analyzer II (at a current
cost of approximately $1,000) because we focused on well-known
targets of mutation in GBM. However, the method would be
straightforward to scale up with regard to patient sample size and
number of genes tested, particularly as costs decline and selective
DNA capture methods develop. Additionally, the cellular
resolution achieved here will improve – recent publications have
demonstrated the promise of the ultimate in cellular resolution by
sequencing at the single-cell level [3]. With these and other near-
term technological advancements, extensions of the approach we
have presented here will allow further progress toward the goal of
personalized medicine via individual tumor sequencing.
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